HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice.

AbstractBACKGROUND:
We have previously demonstrated that peroxisome proliferator-activated receptor (PPARγ) activation inhibits hepatocarcinogenesis. We aim to investigate the effect of PPARγ on hepatocellular carcinoma (HCC) metastatic potential and explore its underlying mechanisms.
METHODS:
Human HCC cells (MHCC97L, BEL-7404) were infected with adenovirus-expressing PPARγ (Ad-PPARγ) or Ad-lacZ and treated with or without PPARγ agonist (rosiglitazone). The effects of PPARγ on cell migration and invasive activity were determined by wound healing assay and Matrigel invasive model in vitro, and in an orthotopic liver tumour metastatic model in mice.
RESULTS:
Pronounced expression of PPARγ was demonstrated in HCC cells (MHCC97L, BEL-7404) treated with Ad-PPARγ, rosiglitazone or Ad-PPARγ plus rosiglitazone, compared with control (Ad-LacZ). Such induction markedly suppressed HCC cell migration. Moreover, the invasiveness of MHCC97L and BEL-7404 cells infected with Ad-PPARγ, or treated with rosiglitazone was significantly diminished up to 60%. Combination of Ad-PPARγ and rosiglitazone showed an additive effect. Activation of PPARγ by rosiglitazone significantly reduced the incidence and severity of lung metastasis in an orthotopic HCC mouse model. Key mechanisms underlying the effect of PPARγ in HCC include upregulation of cell adhesion genes, E-cadherin and SYK (spleen tyrosine kinase), extracellular matrix regulator tissue inhibitors of metalloproteinase (TIMP) 3, tumour suppressor gene retinoblastoma 1, and downregulation of pro-metastatic genes MMP9 (matrix metallopeptidase 9), MMP13, HPSE (heparanase), and Hepatocyte growth factor (HGF). Direct transcriptional regulation of TIMP3, MMP9, MMP13, and HPSE by PPARγ was shown by ChIP-PCR.
CONCLUSION:
Peroxisome proliferator-activated receptor-gamma exerts an inhibitory effect on the invasive and metastatic potential of HCC in vitro and in vivo, and is thus, a target for the prevention and treatment of HCC metastases.
AuthorsB Shen, E S H Chu, G Zhao, K Man, C-W Wu, J T Y Cheng, G Li, Y Nie, C M Lo, N Teoh, G C Farrell, J J Y Sung, J Yu
JournalBritish journal of cancer (Br J Cancer) Vol. 106 Issue 9 Pg. 1486-94 (Apr 24 2012) ISSN: 1532-1827 [Electronic] England
PMID22472882 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers, Tumor
  • Cadherins
  • Hypoglycemic Agents
  • PPAR gamma
  • RNA, Messenger
  • Thiazolidinediones
  • Rosiglitazone
Topics
  • Animals
  • Biomarkers, Tumor (genetics, metabolism)
  • Blotting, Western
  • Cadherins
  • Carcinoma, Hepatocellular (drug therapy, metabolism, pathology)
  • Cell Adhesion (drug effects)
  • Cell Movement (drug effects)
  • Chromatin Immunoprecipitation
  • Gene Expression Profiling
  • Humans
  • Hypoglycemic Agents (pharmacology)
  • In Vitro Techniques
  • Liver Neoplasms (drug therapy, metabolism, pathology)
  • Lung Neoplasms (drug therapy, metabolism, secondary)
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Oligonucleotide Array Sequence Analysis
  • PPAR gamma (agonists, metabolism)
  • RNA, Messenger (genetics)
  • Real-Time Polymerase Chain Reaction
  • Rosiglitazone
  • Thiazolidinediones (pharmacology)
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: